Vascular device company iVascular has announced the expansion of its therapeutic areas with the launch of a new neurovascular pipeline, having gained CE-mark approval for four devices in this space: the iNdeep microcatheter, iNedit balloon distal access catheter, iNtercept retriever device, and iNstroke 4Fr and 6Fr aspiration catheter.
The company’s neurovascular portfolio has been designed to provide new tools that can help treat ischaemic stroke patients, as per a press release. It will become commercially available in Europe—and will be released in other regions that recognise the CE mark—in 2023.
The release also notes that this launch has been timed with World Stroke Day (29 October) as iVascular aims to raise awareness of high stroke rates as well as the need and opportunity for improvements in prevention and case management.
With these new products, the company’s overall portfolio expands into a new area of treatment providing opportunities in patient care with devices for endovascular, cardiovascular, and now neurovascular, pathologies.
“Achieving CE marking of four devices for ischaemic stroke is further evidence of the great team that makes up iVascular and our goal to continue investing in R&D [research and development] to develop new solutions that help in the treatment of patients,” said iVascular CEO Lluís Duocastella.
The company’s recent release also details that a comprehensive training programme and an investment in clinical data to optimise ischaemic stroke outcomes are already in place for this launch.
